Balazs AB, Chen J, Hong CM, et al. Antibody-based protection against HIV infection by vectored immunoprophylaxis. Nature. 2012;481(7379):81–4.

CAS  Article  Google Scholar 

Mascola JR, Stiegler G, VanCott TC, et al. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med. 2000;6(2):207–10.

CAS  PubMed  Article  Google Scholar 

Corey L, Gilbert PB, Juraska M, et al. Two randomized trials of neutralizing antibodies to prevent HIV-1 acquisition. N Engl J Med. 2021;384(11):1003–14.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Ugolini S, Mondor I, Parren PW, et al. Inhibition of virus attachment to CD4+ target cells is a major mechanism of T cell line-adapted HIV-1 neutralization. J Exp Med. 1997;186(8):1287–98.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Reh L, Magnus C, Schanz M, et al. Capacity of broadly neutralizing antibodies to inhibit HIV-1 cell–cell transmission is strain- and epitope-dependent. PLoS Pathog. 2015;11(7):e1004966.

PubMed  PubMed Central  Article  CAS  Google Scholar 

Caskey M, Klein F, Lorenzi JCC, et al. Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. Nature. 2015;522(7557):487–91.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Bournazos S, Klein F, Pietzsch J, et al. Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity. Cell. 2014;158(6):1243–53.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Asokan M, Dias J, Liu C, et al. Fc-mediated effector function contributes to the in vivo antiviral effect of an HIV neutralizing antibody. Proc Natl Acad Sci USA. 2020;117(31):18754–63.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Hessell AJ, Hangartner L, Hunter M, et al. Fc receptor but not complement binding is important in antibody protection against HIV. Nature. 2007;449(7158):101–4.

CAS  PubMed  Article  PubMed Central  Google Scholar 

Wang P, Gajjar MR, Yu J, et al. Quantifying the contribution of Fc-mediated effector functions to the antiviral activity of anti-HIV-1 IgG1 antibodies in vivo. Proc Natl Acad Sci USA. 2020;117(30):18002–9.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Parsons MS, Lee WS, Kristensen AB, et al. Fc-dependent functions are redundant to efficacy of anti-HIV antibody PGT121 in macaques. J Clin Investig. 2019;129(1):182–91.

PubMed  Article  PubMed Central  Google Scholar 

Carpenter MC, Ackerman ME. Recent insights into Fc-mediated effector responses to HIV-1. Curr Opin HIV AIDS. 2020;15(5):282–9.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Ackerman ME, Moldt B, Wyatt RT, et al. A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples. J Immunol Methods. 2011;366(1–2):8–19.

CAS  PubMed  Article  PubMed Central  Google Scholar 

Hezareh M, Hessell AJ, Jensen RC, et al. Effector function activities of a panel of mutants of a broadly neutralizing antibody against human immunodeficiency virus type 1. J Virol. 2001;75(24):12161–8.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Forthal DN, Gilbert PB, Landucci G, et al. Recombinant gp120 vaccine-induced antibodies inhibit clinical strains of HIV-1 in the presence of Fc receptor-bearing effector cells and correlate inversely with HIV infection rate. J Immunol. 2007;178(10):6596–603.

CAS  PubMed  Article  PubMed Central  Google Scholar 

Gomez-Roman VR, Florese RH, Patterson LJ, et al. A simplified method for the rapid fluorometric assessment of antibody-dependent cell-mediated cytotoxicity. J Immunol Methods. 2006;308(1–2):53–67.

CAS  PubMed  Article  PubMed Central  Google Scholar 

Asmal M, Sun Y, Lane S, et al. Antibody-dependent cell-mediated viral inhibition emerges after simian immunodeficiency virus SIVmac251 infection of rhesus monkeys coincident with gp140-binding antibodies and is effective against neutralization-resistant viruses. J Virol. 2011;85(11):5465–75.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Felber BK, Lu Z, Hu X, et al. Co-immunization of DNA and protein in the same anatomical sites induces superior protective immune responses against SHIV challenge. Cell Rep. 2020;31(6):107624.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Florese RH, Demberg T, Xiao P, et al. Contribution of nonneutralizing vaccine-elicited antibody activities to improved protective efficacy in rhesus macaques immunized with Tat/Env compared with multigenic vaccines. J Immunol. 2009;182(6):3718–27.

CAS  PubMed  Article  PubMed Central  Google Scholar 

Hidajat R, Xiao P, Zhou Q, et al. Correlation of vaccine-elicited systemic and mucosal nonneutralizing antibody activities with reduced acute viremia following intrarectal simian immunodeficiency virus SIVmac251 challenge of rhesus macaques. J Virol. 2009;83(2):791–801.

CAS  PubMed  Article  PubMed Central  Google Scholar 

Ackerman ME, Das J, Pittala S, et al. Route of immunization defines multiple mechanisms of vaccine-mediated protection against SIV. Nat Med. 2018;24(10):1590–8.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Om K, Paquin-Proulx D, Montero M, et al. Adjuvanted HIV-1 vaccine promotes antibody-dependent phagocytic responses and protects against heterologous SHIV challenge. PLoS Pathog. 2020;16(9):e1008764.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Barouch DH, Alter G, Broge T, et al. Protective efficacy of adenovirus/protein vaccines against SIV challenges in rhesus monkeys. Science. 2015;349(6245):320–4.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Alter G, Yu WH, Chandrashekar A, et al. Passive transfer of vaccine-elicited antibodies protects against SIV in rhesus macaques. Cell. 2020;183(1):185–96 e14.

Baum LL, Cassutt KJ, Knigge K, et al. HIV-1 gp120-specific antibody-dependent cell-mediated cytotoxicity correlates with rate of disease progression. J Immunol. 1996;157(5):2168–73.

CAS  PubMed  PubMed Central  Google Scholar 

Ahmad R, Sindhu ST, Toma E, et al. Evidence for a correlation between antibody-dependent cellular cytotoxicity-mediating anti-HIV-1 antibodies and prognostic predictors of HIV infection. J Clin Immunol. 2001;21(3):227–33.

CAS  PubMed  Article  PubMed Central  Google Scholar 

Forthal DN, Landucci G, Daar ES. Antibody from patients with acute human immunodeficiency virus (HIV) infection inhibits primary strains of HIV type 1 in the presence of natural-killer effector cells. J Virol. 2001;75(15):6953–61.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Stratov I, Chung A, Kent SJ. Robust NK cell-mediated human immunodeficiency virus (HIV)-specific antibody-dependent responses in HIV-infected subjects. J Virol. 2008;82(11):5450–9.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Chung AW, Navis M, Isitman G, et al. Activation of NK cells by ADCC antibodies and HIV disease progression. J Acquired Immune Deficiency Syndr. 2011;58(2):127–31.

CAS  Article  Google Scholar 

Johansson SE, Rollman E, Chung AW, et al. NK cell function and antibodies mediating ADCC in HIV-1-infected viremic and controller patients. Viral Immunol. 2011;24(5):359–68.

CAS  PubMed  Article  Google Scholar 

Wren LH, Chung AW, Isitman G, et al. Specific antibody-dependent cellular cytotoxicity responses associated with slow progression of HIV infection. Immunology. 2013;138(2):116–23.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Lambotte O, Ferrari G, Moog C, et al. Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllers. AIDS. 2009;23(8):897–906.

CAS  PubMed  Article  Google Scholar 

Lambotte O, Pollara J, Boufassa F, et al. High antibody-dependent cellular cytotoxicity responses are correlated with strong CD8 T cell viral suppressive activity but not with B57 status in HIV-1 elite controllers. PLoS ONE. 2013;8(9):e74855.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Forthal DN, Landucci G, Haubrich R, et al. Antibody-dependent cellular cytotoxicity independently predicts survival in severely immunocompromised human immunodeficiency virus-infected patients. J Infect Dis. 1999;180(4):1338–41.

CAS  PubMed  Article  Google Scholar 

Ackerman ME, Dugast AS, McAndrew EG, et al. Enhanced phagocytic activity of HIV-specific antibodies correlates with natural production of immunoglobulins with skewed affinity for FcγR2a and FcγR2b. J Virol. 2013;87(10):5468–76.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Ackerman ME, Crispin M, Yu X, et al. Natural variation in Fc glycosylation of HIV-specific antibodies impacts antiviral activity. J Clin Investig. 2013;123(5):2183–92.

CAS  PubMed